Olmesartan + Hidroclorotiazida Sandoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan + Hidroclorotiazida Sandoz, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, to help lower blood pressure in adult patients. GNH USA supplies Olmesartan + Hidroclorotiazida Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan + Hidroclorotiazida Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals pharmacies and clinics worldwide.

Olmesartan medoxil combined with hydrochlorothiazide is used in cardiovascular therapy to manage blood pressure through dual mechanisms.

- Hypertension: Improves blood pressure control when monotherapy is insufficient. - Heart failure: Assists in reducing fluid overload and blood pressure in selected patients. - Diabetic nephropathy: Helps slow progression by controlling hypertension. - Post‑myocardial infarction: Supports blood pressure management as part of secondary prevention. - Chronic kidney disease: Contributes to blood pressure reduction in patients with renal impairment. - High‑risk cardiovascular risk patients with multiple risk factors to lower overall cardiovascular risk.

Olmesartan + hydrochlorothiazide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headed at low blood pressure. - Headache. - Fatigue. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia or severe electrolyte imbalance. - Angio‑edema. - Liver function abnormalities. - Blood‑cell disorders such as agranulocytosis. - Pancreatitis. - Severe skin reactions (e.g., Stevens‑Johnson syndrome).

Olmesartan + hydrochlorothiazide should be used with careful clinical oversight, especially in patients with specific health considerations.

- Renal impairment: Adjust dose and monitor kidney function. - Electrolyte imbalance: Check serum electrolytes regularly. - Hepatic disease: Use cautiously; monitor liver enzymes. - Pregnancy: Contra‑indicated in the second and third trimesters; avoid unless benefits outweigh risks. - Elderly patients: Start with lower dose and titrate slowly. - Drug‑induced photosensitivity: Advise patients to limit sun exposure. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan + hydrochlorothiazide has several clinically relevant drug interactions that may require dose adjustment or monitoring.

Major Interactions (Avoid): - Potassium‑rich supplements : Elevated risk of hyper‑hyper k . - ACE‑inhibitors : Additive risk of hypotension and renal impairment. - NSAIDs : May reduce antihy antih .

Moderate  -  t  t -  t.